Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial
ASi in CKD group, Katherine R. Tuttle*, Sibylle J. Hauske, Maria Eugenia Canziani, Maria Luiza Caramori, David Cherney, Lisa Cronin, Hiddo J.L. Heerspink, Christian Hugo, Masaomi Nangaku, Ricardo Correa Rotter, Arnold Silva, Shimoli V. Shah, Zhichao Sun, Dorothea Urbach, Dick de Zeeuw, Peter Rossing
Research output: Contribution to journal › Article › Academic › peer-review
105Citations
(Scopus)
921Downloads
(Pure)
Fingerprint
Dive into the research topics of 'Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial'. Together they form a unique fingerprint.